

Effects of nicotine compared to placebo gum on sensitivity to pain and mediating effects of peak alpha frequency

Reviewed Preprint

Published from the original preprint after peer review and assessment by eLife.

About eLife's process

Reviewed preprint posted

November 17, 2023 (this version)

Sent for peer review

September 1, 2023

Posted to bioRxiv

August 14, 2023

Samantha K. Millard, Alan K.I. Chiang, Peter Humburg, Nahian Chowdhury, Raafay Rehan, Andrew J. Furman, Ali Mazaheri, Siobhan M. Schabrun, David A. Seminowicz

Faculty of Medicine, Wallace Wurth Building, University of New South Wales (UNSW), Sydney, NSW 2052, Australia • Centre for Pain IMPACT, Neuroscience Research Australia (NeuRA), 139 Barker Street, Randwick, Sydney, NSW 2031, Australia • Mark Wainwright Analytical Centre, Biological Sciences South Building, University of New South Wales (UNSW), Sydney, NSW 2052, Australia • Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA • Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD 21201, USA • Center to Advance Chronic Pain Research, University of Maryland Baltimore, Baltimore, MD 21201, USA • School of Psychology, University of Birmingham, Birmingham, B15 2TT, UK • Centre for Human Brain Health (CHBH), University of Birmingham, Birmingham, B15 2TT, UK • The Gray Centre for Mobility and Activity, Parkwood Institute, London, Ontario, Canada • School of Physical Therapy, University of Western Ontario, London, Ontario, Canada • Department of Medical Biophysics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

Recent research has linked individual peak alpha frequency (PAF) to pain sensitivity, but whether PAF alterations can influence pain remains unclear. Our study investigated the effects of nicotine on pain sensitivity and whether pain changes are mediated by PAF changes. In a randomised, double-blind, placebo-controlled experiment, 62 healthy adults (18–44 years) received either 4 mg nicotine gum (n=29) or placebo (n=33). Resting state EEG and pain ratings during prolonged heat and pressure models were collected before and after nicotine intake. Nicotine reduced heat pain ratings and increased PAF speed across the scalp, driven by changes at centralparietal and right-frontal regions. However, mediation analysis did not support the notion that PAF changes mediate nicotine's effects on pain sensitivity. While a growing body of literature supports a link between PAF and both acute and chronic pain, further work is needed to understand the mechanisms of this link.

eLife assessment

In this **useful** study, Millard et al. assessed the effects of nicotine on pain sensitivity and peak alpha frequency (PAF). The evidence shown is **incomplete** to support the key claim that nicotine modulates PAF or pain sensitivity, considering the effect sizes observed. This raises the question of whether the chosen experimental intervention was the most suitable approach for investigating their research question. Nonetheless, the work can be incorporated into the literature investigating the relationship between nicotine and pain, and could be of broad interest to pain researchers.

1 Introduction

Chronic pain is a highly prevalent and multifaceted health issue, which produces significant physical, emotional, and economic burden to those in pain, their families and friends, health care systems, and society [1–3]. The ability to identify those at greater risk of developing chronic pain is limited, but could be critical for reducing the prevalence and burden of chronic pain [4–6]. Individual peak alpha frequency (PAF) is an electro-physiological brain measure that shows promise as a biomarker of pain sensitivity, and thus may prove useful for predicting chronic pain development [7–12]. Although the number of studies investigating PAF as a predictor of pain is increasing [13–17], no experiments have manipulated PAF while also measuring pain, which has limited our understanding of whether, and how, PAF is mechanistically linked to pain sensitivity.

PAF refers to the dominant oscillatory frequency in the 8–12 Hz alpha range. As alpha oscillations are believed to represent periodic inhibitory processes that direct temporal aspects of sensory information processing [18,19], it is thought that PAF reflects the rate at which sensory information is sampled from the external environment [20–22]. In the context of pain, slower PAF speed has been associated with the presence and duration of chronic pain [16,23–27], while in healthy, pain-free individuals, slower PAF has been associated with higher pain sensitivity in experimental pain models [8–10] and acute post-surgical settings [11].

While previous studies suggest that PAF could be used as either a biomarker for disease progression or as a predictive biomarker for pain sensitivity, critical gaps remain in our understanding of how PAF is mechanistically linked to pain. Specifically, no study has examined whether the manipulation of PAF alters pain sensitivity. Addressing this question has significant implications, as it would determine i) whether PAF is causally implicated in pain processing, and ii) whether manipulation of PAF has relevance as a method of clinical pain modulation. Several methods have been used to alter individual PAF, including brain stimulation [28–30], exercise [31–33], visual stimulation [34,35], cognitive tasks [36], and nicotine [37–39]. A large body of evidence suggests that nicotine is an ideal choice for manipulating PAF, as both nicotine and smoking increase PAF speed [37,40–47] as well as pain thresholds and tolerance [48–52]. Thus, the primary questions addressed in this study were whether nicotine can: i) increase peak alpha frequency (PAF), ii) reduce pain sensitivity, and iii) determine whether changes in pain sensitivity are mediated by changes in PAF speed.

A secondary question pertains to the nature of the PAF–pain relationship. A substantial proportion of the current literature suggests that slower PAF speed is associated with higher pain sensitivity [8–11,16,23–26]. However, conflicting findings exist, with some studies reporting no relationship between PAF and chronic pain [53–56], or an opposite relationship where faster

PAF is associated with higher pain sensitivity in experimental pain settings [7,14]. Divergent results could be due to variations in the relationship between PAF and different types of pain, or the dependence of this relationship on individual factors. For example, it was recently suggested that PAF–pain relationships may only be observed in neuropathic pain or expressed differently in males and females [16]. One way to address this issue is to investigate PAF across multiple pain models [12]; currently the PAF–pain relationship has been studied using thermal [7,8,10], musculoskeletal [9,14], and surgical [11] pain, but never with multiple pain modalities included in the same study. Thus, a secondary question was whether baseline PAF, measured in a pain-free resting state, correlated with pain sensitivity during a model of heat pain (i.e. PHP), which has been previously assessed and is negatively correlated with PAF [10], and a model of pressure pain (i.e. cuff pressure algometry; CPA [57–61]) that has not been assessed in relation to PAF. Applying two experimental pain models also allows assessment of the generalisability of nicotine’s effects on pain and the potential mediating effects of PAF, including whether these effects are consistent across different types of pain.

Using a randomised, placebo-controlled, double-blind, parallel design, a sample of healthy, pain-free, non-smoking participants had their resting state PAF measured before and after two models of prolonged pain (i.e. CPA and PHP; pre-gum). Participants then chewed either nicotine or placebo gum, after which their resting state PAF was re-assessed before and after the two prolonged pain models (i.e. CPA and PHP; post-gum). We predicted that: 1. nicotine gum would increase PAF speed in comparison to placebo gum; 2. nicotine gum would decrease pain ratings in comparison to placebo gum; 3. decreases in pain ratings following nicotine gum would be mediated by increases in the speed of PAF; and 4. faster baseline PAF would be associated with lower baseline pain ratings. Based on a pre-registered analysis plan (<https://osf.io/2yaxz/>), predictions 1–3 were tested using two-wave latent change score (2W-LCS) mediation models [62–64], while prediction 4 was tested using correlation analysis.

2 Results

The statistical analysis plan for this study was pre-registered on Open Science Framework (OSF: <https://osf.io/2yaxz/>) in July 2022.

2.1 Sample Characteristics

The participant sample included 62 healthy adults (26.45 ± 7.28 ; range: 18–44 years), without neurological or psychological disorders. Fourteen participants self-identified as North-West European (22.58%), 12 as South-East Asian, (19.36%), and eight reported mixed ancestries (12.90%; see Supplementary Material 1 for a full list of self-reported ancestry). There were 32 females (24.53 ± 6.52 ; range: 18–43 years) and 30 males (28.5 ± 7.58 ; range: 19–44 years); no participants reported their sex at birth as inter-sex. Thirty-one individuals identified as women, 30 as men, and 1 as non-binary.

Regarding pain in the past two weeks, 20 participants reported “None” (nicotine: $n = 10$; placebo: $n = 10$), 16 reported “Very Mild” (nicotine: $n = 14$; placebo: $n = 12$), 15 reported “Mild” (nicotine: $n = 5$; placebo: $n = 10$), one reported “Moderate” (nicotine: $n = 1$, placebo: $n = 0$), and no participants reported “Severe” pain in the past two weeks. Participants were successfully blinded to group allocation (Supplementary Material 2) and the remaining baseline demographics are displayed in **Table 1**. Following CONSORT recommendations [65,66], no baseline statistics are reported.

Group	N = 62	Nicotine (n = 29)	Placebo (n = 33)
Age	26.45 (± 7.28)	26.18 (± 8.06)	26.39 (± 6.65)
Weight (kg)	68.16 (± 13.42)	68.9 (± 13.00)	67.5 (± 13.90)
Height (cm)	172.29 (± 10.08)	172.40 (± 10.00)	172.20 (± 10.30)
Depressive	0.53 (± 0.97)	0.62 (± 1.10)	0.46 (± 0.75)
Anxiety	0.69 (± 1.06)	0.76 (± 1.30)	0.64 (± 0.82)
Stress	9.82 (± 3.81)	8.93 (± 4.04)	10.61 (± 3.48)
Sleep quality	6.97 (± 1.77)	6.79 (± 1.86)	7.12 (± 1.71)
Heat pain threshold	41.27 (± 2.59)	40.97 (± 2.79)	41.54 (± 2.41)
Pressure threshold	293.92 (± 121.21)	318.70 (± 111.25)	272.14 (± 127.00)
Alpha power (8–12 Hz)	26.24 (± 7.02)	25.89 (± 7.64)	26.55 (± 6.54)

Note. PAF = peak alpha frequency; PHP = phasic heat pain; CPA = cuff pressure algometry.

Table 1

Mean $\pm$ standard deviations (SD) for baseline participant characteristics split by gum group.

2.2 Effects of nicotine gum on alpha oscillations and prolonged pain ratings

Mediation analysis was conducted to assess the effects of nicotine on PAF and pain ratings, and whether change in PAF mediated change in pain.

ANCOVA-equivalent two-wave latent change score (2W-LCS) models (i.e. with autoregressive and coupling parameters) and difference score 2W-LCS models (i.e. without auto-regressive and coupling parameters) were constructed for mean PHP and CPA pain outcomes separately (see Methods for further details). As no significant difference was found between model fits (see Supplementary Materials 3.1 and 3.2), the difference score 2W-LCS models are reported here; whilst the full ANCOVA-equivalent 2W-LCS models are presented in Supplementary Material 3.1.

Nicotine gum modulated global PAF (8–12 Hz) and PHP ratings, but change in PHP ratings were not mediated by change in PAF

The PHP model consisted of five repetitions of a 40 second heat stimulation to the inside left forearm at a fixed 46 °C (see Methods), which was most frequently described as moderate/severe hot, sharp, and shooting pain (**Figure 1**, plot A). Raw time courses of pain ratings during PHP are displayed in **Figure 1** (plot C), from which the mean pain during max heat stimulation was calculated (**Table 2**, **Figure 1**, plot E).

Five participants could not tolerate the fixed 46 °C stimulus during familiarisation, therefore a lower temperature of 45 °C was used for both pre- and post-gum PHP assessments for these participants, as reported in the protocol (see Methods). Two participants were excluded from mediation analysis assessing the effects of nicotine on PHP ratings: one from the placebo group due to an equipment issue during the second pain assessment, and one from the nicotine group that could not tolerate the baseline temperature for the second pain assessment (nicotine: $n = 28$; placebo: $n = 32$).

The difference score model for PHP (**Figure 3**; model fit: $\chi^2(24) = 25.874$, $p = 0.36$, CFI = 0.99, RMSEA = 0.036, SRMR = 0.078) suggests a significant total ($b = -0.62$, $p = .023$, bootstrapped 95% CI: [-1.21, -0.15]) and direct ($b = -0.68$, $p = .021$, bootstrapped 95% CI: [-1.28, -0.16]) effect of nicotine on change in PHP ratings (**Figure 1**). Change in pain was reduced by a factor of -0.667 for the nicotine group compared to the placebo group when controlling for confounding variables (**Figure 3**).

Frequency spectra (plots A and B) and topographical plots (plot E) of PAF pre-post nicotine, are displayed by group in **Figure 2**, with PAF values displayed in **Table 3**. The difference score model suggests a significant effect of nicotine gum on change in global PAF ($b = 0.085$, $p = .018$, bootstrapped 95% CI: [0.017, 0.15]), suggesting change in PAF was increased by a factor of 0.085 for the nicotine group compared to placebo when controlling for confounding variables (**Figure 3**). Therefore, nicotine changed PAF and PHP ratings in the predicted directions compared to what would be expected without nicotine (i.e. placebo). However, as the estimated effect of change in PAF speed on change in PHP ratings was non-significant ($b = 0.23$, $p = .78$, bootstrapped 95% CI: [-1.28, 1.9]), the change in PAF did not mediate the change in PHP ratings (i.e. indirect effect; $b = 0.019$, $p = .81$, bootstrapped 95% CI: [-0.093, 0.23]).

There was also a significant effect of perceived stress at baseline on change in PHP ratings when controlling for group allocation and other confounding variables ($b = -0.096$, $p = .048$, bootstrapped 95% CI: [-0.19, -0.000047]), where higher perceived stress resulted in larger decreases in PHP ratings. There was also a significant effect of sex on change in PAF ($b = -0.077$, $p = .037$, bootstrapped 95% CI: [-0.16, -0.011]); change in PAF was reduced by a factor of -0.077 for males

Gum group	Time point	PHP		CPA	
		n	Mean ($\pm$ SD)	n	Mean ($\pm$ SD)
Total	Pre	62	5.66 ($\pm$ 2.34)	62	4.58 ($\pm$ 1.53)
	Post	60	5.81 ($\pm$ 2.50)	62	3.70 ($\pm$ 1.93)
Nicotine	Pre	29	5.73 ($\pm$ 2.13)	29	4.95 ($\pm$ 1.43)
	Post	28	5.78 ($\pm$ 2.33)	29	3.97 ($\pm$ 1.76)
Placebo	Pre	33	5.60 ($\pm$ 2.55)	33	4.26 ($\pm$ 1.57)
	Post	32	5.84 ($\pm$ 2.67)	33	3.46 ($\pm$ 2.07)

Table 2

Mean $\pm$ standard deviations (SD) for pain ratings during phasic heat pain (PHP) and cuff pressure algometry (CPA), for pre- and post-gum, for the whole sample and separated by nicotine and placebo groups.




Figure 1

Percentage of participants reporting each category descriptor of pain on the McGill pain questionnaire for A) phasic heat pain (PHP) and B) cuff pressure algometry (CPA) at baseline. Average pain time courses split into nicotine (orange, $n = 29$) and placebo (grey, $n = 33$) gum groups for C) PHP and D) CPA models of prolonged pain. Raincloud plots of mean pain ratings during E) PHP and F) CPA models of prolonged pain.




Figure 2

A) Individual spectral plots of eyes closed (EC) resting state EEG data showing dominant peaks within the alpha range of 8–12 Hz. Note that many participants' peaks fall outside the narrow 9–11 Hz window. Top panel shows individual spectra for participants in the placebo group (in grey, n = 33), bottom panel shows individual spectra for participants in the nicotine group (in orange, n = 29). B) Spectral plots of eyes closed (EC) resting state EEG shows averaged spectra by group and time point. C) Raincloud plots of mean global and D) sensorimotor PAF values, calculated with a wide window (8–12 Hz) and the centre of gravity method, before and after chewing either nicotine (in orange) or placebo (in grey) gum. E) Topographical plots of PAF calculated for each electrode with the centre of gravity method and 8–12 Hz window are shown for the pre-gum baseline (rest 1) and post-gum (rest 3). F) Topographical plot of t-test statistics produced by cluster-based permutation analysis of nicotine group, displaying significant difference in PAF after chewing nicotine gum in two separate clusters marked by crosses (x).




Figure 3

Path model displaying unstandardised estimates and p-values for the difference score two-wave latent change score (2W-LCS) model assessing the effect of nicotine against placebo (i.e. gum group) on change in global 8–12 Hz peak alpha frequency (i.e. Δ_{PAF}) and change in mean phasic heat pain (PHP) ratings (i.e. Δ_{Pain}). Green arrows highlight the indirect effects (i.e. a and b), the red arrow highlights the direct effect (i.e. c'), the blue lines highlight pre-determined confounding variables, and dashed lines denote fixed effects. This model suggests that chewing nicotine gum, compared to placebo, increases the speed of PAF, and decreases PHP ratings, however the change in PAF does not influence the change in PHP ratings, therefore changes in PHP ratings after nicotine gum are not mediated by changes in PAF.

Gum group	Time point	n	Sensorimotor			
			PAF		Global PAF	
			Mean ($\pm$ SD)	Median	Mean ($\pm$ SD)	Median
Total	Pre	62	9.90 ($\pm$ 0.37)	9.90	9.96 ($\pm$ 0.41)	9.98
	Post	62	9.92 ($\pm$ 0.41)	9.89	9.98 ($\pm$ 0.43)	9.97
Nicotine	Pre	29	9.82 ($\pm$ 0.36)	9.80	9.86 ($\pm$ 0.37)	9.85
	Post	29	9.88 ($\pm$ 0.42)	9.88	9.93 ($\pm$ 0.44)	9.94
Placebo	Pre	33	9.97 ($\pm$ 0.38)	9.97	10.04 ($\pm$ 0.42)	10.06
	Post	33	9.96 ($\pm$ 0.41)	9.94	10.02 ($\pm$ 0.43)	10.00

Table 3

Mean $\pm$ standard deviations (SD) for sensorimotor and global peak alpha frequency (PAF) pre- and post-gum chewing, for the whole sample and by nicotine and placebo groups. PAF calculated for wide frequency window (8–12 Hz) with the centre of gravity method.

compared to females when controlling for gum group and confounders, therefore the increase in PAF speed was greater for females than males (see Supplementary Material 3.3 for exploratory analysis of sex differences).

A complete table of PAF and power values for all four time points is displayed in Supplementary Material 4.1. Exploratory analysis of interactions between time point (i.e. pre-/post-gum) and group (i.e. nicotine/placebo) on PHP ratings, PAF speed, PHP ratings, and alpha power, using repeated measures analysis of variance (RMANOVA) that do not control for confounding, are displayed in Supplementary Materials 4 and 5. Notably, exploratory RM-ANOVAs still indicated interactions between gum group and time point on PAF (8–12 Hz) indicating that PAF only increased for the nicotine group after chewing (Supplementary Material 4), but there was no interaction between gum group and time point on PHP ratings (Supplementary Material 5), underscoring the necessity of controlling for confounding variables.

Cluster-based permutation analysis

The effect of nicotine on PAF speed was only significant for global PAF with a wide frequency window (8–12 Hz) and not for sensorimotor PAF (i.e. Cz, C1, C2, C3, C4) or narrow frequency windows (9–11 Hz; Supplementary Materials 3.4–3.6). This suggests that nicotine produces change in PAF somewhere in sensor-space, but not in the pre-defined sensorimotor region comprising central electrodes. An exploratory cluster-based permutation analysis (see Methods) showed significant increases in PAF speed after chewing nicotine gum, with this effect being maximal over two spatially separated clusters of electrodes: one cluster over the central-parietal region, and another over the right-frontal region (**Figure 2** [↗](#), plot F). None of the electrodes exceeded the threshold of .05 to be clustered in the placebo group.

Nicotine gum modulated global PAF (8–12 Hz), with no total, direct, or indirect effects on CPA ratings

The CPA model involved four minutes of continuous cuff pressure to the left calf muscle that was initially calibrated to each individual's 4/10 pain (see Methods), and was most frequently described as mild/moderate cramping, aching, throbbing, and heavy pain (**Figure 1** [↗](#), plot B). Raw time courses of pain ratings during CPA are displayed in **Figure 1** [↗](#) (plot D), from which mean pain during the 4 minutes of stimulation was calculated (**Table 2** [↗](#), **Figure 1** [↗](#), plot F). No participants were excluded from the analyses of pressure pain (nicotine: $n = 29$; placebo: $n = 33$).

Estimates from the difference score 2W-LCS model for CPA pain ratings (**Figure 4** [↗](#)) for total ($b = -0.28$, $p = .50$, bootstrapped 95% CI: [-1.13, 0.49]), direct ($b = -0.17$, $p = .69$, bootstrapped 95% CI: [-1.07, 0.59]), and indirect ($b = -0.11$, $p = .53$, bootstrapped 95% CI: [-0.61, 0.18]) effects of nicotine on mean CPA ratings were nonsignificant (model fit: $\chi^2(24) = 29.55$, $p = 0.20$, CFI = 0.97, RMSEA = 0.061, SRMR = 0.085). Therefore, there was no evidence to suggest that nicotine gum directly or indirectly influenced change in CPA ratings.

Consistent with the PHP model, there was a significant effect of nicotine gum on change in global PAF (8–12 Hz) speed ($b = 0.089$, $p = .011$, bootstrapped 95% CI: [0.018, 0.16]), where change in PAF speed increased by 0.089 for the nicotine group compared to the placebo group. Additionally, there was again an effect of sex on change in PAF ($b = -0.076$, $p = .027$, bootstrapped 95% CI: [-0.15, -0.01]), where the increase in PAF speed was greater for females than males. And the estimated effect of change in PAF speed on change in pain ratings was non-significant for CPA ($b = -1.28$, $p = .49$, bootstrapped 95% CI: [-5.21, 2.11]).

Exploratory analysis of interactions between time point (i.e. pre-/post-gum) and group (i.e. nicotine/placebo) on CPA ratings using RM-ANOVA (Supplementary Material 5) suggested that CPA pain ratings decreased after chewing gum irrespective of group (**Figure 1** [↗](#), plots D and F).




Figure 4

Path model displaying unstandardised estimates and p-values for the difference score two-wave latent change score (2W-LCS) model assessing the effect of nicotine against placebo (i.e. gum group) on change in global 8-12 Hz peak alpha frequency (i.e. Δ_{PAF}) and change in mean cuff pressure algometry (CPA) ratings (i.e. Δ_{Pain}). Green arrows highlight the indirect effects (i.e. a and b), the red arrow highlights the direct effect (i.e. c'), the blue lines highlight pre-determined confounding variables, and dashed lines denote fixed effects. This model suggests that chewing nicotine gum, compared to placebo, increases the speed of PAF and does not influence CPA ratings, directly or indirectly.

Summary of mediation analyses

In summary, nicotine demonstrated significant total and direct effects on pain intensity ratings (i.e., reduction compared to placebo) during PHP, but not during CPA, where pain ratings decreased irrespective of gum group. There was also a significant effect of nicotine on change in global PAF speed (i.e., increased compared to placebo). However, there was no evidence of an indirect effect, suggesting that the change in PAF speed did not mediate the change in pain intensity ratings during PHP.

2.3 Relationship between PAF and pain at baseline

Evidence for negative correlations between pre-gum PAF (8–12 Hz) and pre-gum pain ratings during PHP ($r = -0.14$, $BF_{10} = 0.52$) and during CPA ($r = -0.086$, $BF_{10} = 0.33$; **Figure 5**) is inconclusive. Therefore, there was no evidence for or against slower PAF being associated with higher pain ratings. However, in an exploratory analysis of separate correlations in males and females (**Figure 5**, plot C), there was moderate evidence for a negative relationship between global PAF (8–12 Hz) and PHP ratings in males ($r = -0.39$, $BF_{10} = 3.22$). In contrast, the evidence for a relationship between global PAF and PHP ratings in females was equivocal ($r = -0.032$, $BF_{10} = 0.40$). Separating by sex for the correlations between PAF and CPA ratings still produced inconclusive evidence for a relationship (males: $r = -0.23$, $BF_{10} = 0.61$; females: $r = -0.086$, $BF_{10} = 0.40$).

The relationship between PAF and pain was also assessed using median splits on PAF, showing similar patterns of slower PAF being associated with higher PHP ratings in males only (Supplementary Material 6.1). Correlations between global PAF (8–12 Hz) and max pain during PHP also suggested slower PAF was only associated with higher max PHP ratings in male participants (Supplementary Material 6.2). Five participants could not tolerate the 46 °C stimulus during familiarisation, therefore a lower temperature of 45 °C was used for these participants. Repeat analyses excluding these five participants did not impact the observed relationships (Supplementary Material 6.3).

In summary, the evidence for a relationship between PAF and pain is inconclusive, with the exception of the relationship between PAF and PHP ratings by sex, where there was moderate evidence of a negative correlation in male participants.

3 Discussion

In this pre-registered study, we probed the proposed PAF–pain relationship [8–12] by administration of nicotine – a substance suggested to acutely alter both PAF [45] and pain [49]. Compared to placebo, our data demonstrate three key findings: 1) nicotine increased PAF speed; 2) nicotine reduced prolonged heat pain intensity but not prolonged pressure pain intensity; and 3) decreases in prolonged heat pain intensity were not mediated by changes in PAF. This suggests that changes in heat pain due to nicotine occur through mechanisms unrelated to change in PAF. In addition, we found moderate evidence that 4) slower PAF speed at baseline is associated with higher heat pain ratings at baseline in males but not females. In contrast PAF was not associated with pressure pain ratings for males or females.

3.1 The effect of nicotine on PAF

We aimed to determine whether nicotine gum could increase PAF speed. In line with previous literature in non-smokers [37,46,47], we contribute additional evidence that chewing 4 mg of nicotine gum increases PAF speed in non-smoking nicotine gum naïve, pain-free, adult participants. A cluster-based permutation analysis indicated that the change in wide window PAF




Figure 5

Wide band (8–12 Hz) global peak alpha frequency (PAF) does not correlate with A) mean pain ratings during phasic heat pain (PHP) or B) cuff pressure algometry (CPA). Regression lines and shaded 95% confidence intervals. Correlations separated by sex for females in teal ($n = 32$) and males in brown ($n = 30$) for C) PHP and D) CPA, suggest a strengthening of a negative relationship between sensorimotor PAF and PHP ratings for males ($BF_{10} = 3.22$).

(8–12 Hz) produced by nicotine, was most pronounced in a cluster of electrodes in the central-parietal region and a separate cluster of electrodes in the right-frontal region, rather than in the pre-registered sensorimotor ROI (i.e., Cz, C1, C2, C3, C4).

Interestingly, in addition to effects of nicotine on PAF, the 2W-LCS mediation model suggested that sex also significantly influenced change in PAF, with greater increases in PAF for females compared to males. Notably, the female participants in this study were significantly lighter than the males (Supplementary Material 3.3). However, since the 2W-LCS model did not examine the potential interaction between sex and gum group on change in PAF, conclusions are limited at this stage and future research should investigate these interactions.

3.2 The effect of nicotine on pain

Nicotine is thought to have acute analgesic properties in experimental settings, with a review reporting that nicotine increased pain thresholds and pain tolerance [49]. However, previous research has not assessed the effects of nicotine on prolonged experimental pain models. The present study found that 4 mg of nicotine reduced heat pain ratings during prolonged heat pain compared to placebo, but that prolonged pressure pain decreased irrespective of which gum was chewed. Our findings are thus partly consistent with the idea that nicotine can function as an acute analgesic [49]. We further advance the literature by reporting this effect in a model of prolonged heat pain, which better approximates the experience of clinical pain than short lasting models used to assess thresholds and tolerance [49]. However, we note that the observed effect of nicotine on pain was small in magnitude, bringing into question whether this reduction in pain is meaningful in practice. Future research should examine whether effects on pain increase in magnitude with different nicotine administration regimens (i.e. dose and frequency).

We did not see an analgesic effect for prolonged pressure pain, as ratings during pressure pain were lower at the second assessment irrespective of gum allocation. The way we calibrated the pressure pain model may have impacted our results. Previous literature has used cuff inflation where the cuff pressure increases until the participant reports 4/10 pain, at which point it remains stable for the desired number of minutes [57–59,67]. In contrast, a separate calibration was conducted at the beginning of this experiment to calculate the pressure used for the remainder of the study, based on the average of three trials of increasing pressure to 4/10 pain (see Methods). This method may result in lower pain ratings at the second pain induction with the same pressure in a same-session repeated measures investigation.

Analgesic mechanisms of nicotine are complex [49], likely depending on the type of pain and whether nicotine use is acute or chronic, along with several other contributing factors. For example, in addition to the effect of nicotine on prolonged heat pain ratings, our results suggest an effect of stress on changes in heat pain ratings, with those self-reporting higher stress at baseline having greater reductions in pain. Whether this interacts with the effects of nicotine is unclear, but, as stress is linked to nicotine [68,69] and pain [70–72], these interactions should be explored in future. For those with chronic pain, smoking and nicotine use is reported as a coping strategy for pain [52]; abstinence can increase pain sensitivity [48,50], and pain is thus seen as a barrier to smoking cessation due to fear of worsening pain [51,52]. Therefore, continued understanding of the acute effects of nicotine on models of prolonged pain could improve understanding of the role of nicotine and smoking use in chronic pain [49,51,52].

3.3 The relationship between PAF and pain

Prior research suggests that slower PAF is associated with higher pain sensitivity [8–11], and while the validation of PAF as a predictive biomarker continues [13], the question of whether PAF is mechanistically linked to pain remains unanswered. Modulating PAF speed and pain sensitivity with nicotine is necessary but not sufficient to demonstrate a causal pathway from nicotine to PAF to pain (i.e. intervention → mediator → outcome) [73]. We did not find evidence

for a causal relationship between PAF and pain sensitivity, as our 2W-LCS model did not show a significant mediating (i.e. indirect) effect of change in PAF on change in pain due to nicotine. The implication of this is that pain sensitivity may not be dependent on state changes in PAF, thus changing PAF may not be a useful target for pain modulation. However, as this is the first study to directly manipulate PAF and observe effects on pain, we cannot confidently state that a causal relationship between PAF and pain sensitivity does not exist, and future research should explore these relationships with larger sample sizes, larger doses of nicotine, and alternative PAF modulators.

As an alternative explanation, an indirect effect may exist, but could not be seen in the present study due to the single, low dose of nicotine or for other methodological reasons. For example, the relationship between change in PAF and change in pain may be non-linear, and therefore difficult to see using a 2W-LCS model that is based on linear regression analyses. Additionally, the use of global PAF may have introduced mediation measurement error into our mediation analysis. The spatial precision used in the current study was based on previous literature on PAF as a biomarker of pain sensitivity, which have used global and/or sensorimotor ROIs [8,10]. Identification and use of the exploratory electrode clusters found in this study could build upon the current work and reduce the potential for mediator measurement error in future studies.

Furthermore, there may have been other mediators that suppress the mediating effects of PAF within our model [64,74,75]. This is plausible, as nicotine is thought to act on pain through multiple pathways [50,52,76], and more direct PAF modulation could more definitively evaluate whether PAF is mechanistically linked to pain sensitivity. Future interventions to modulate PAF could use non-invasive brain stimulation (NIBS), such as transcranial alternative current stimulation (tACS) or repetitive transcranial magnetic stimulation (rTMS), to influence the firing of neurons, thereby directly influencing the brain mechanisms producing PAF [77–79].

Regarding the relationship between PAF and pain at baseline, the negative correlation between PAF and pain seen in previous work [7,11,15] was only observed here for male participants during the PHP model for global PAF. Effect sizes for the relationship between PAF and pain ratings from previous work were in the range of $r = 0.4$ – 0.6 [8,11]. In the present study we saw a weaker relationship for PHP pain ($N = 62$, $r = -0.14$). However, sex-stratified analysis demonstrated that males exhibit comparable effect sizes to previous studies ($n = 30$, $r = -0.39$), while females did not show a relationship between PAF and heat pain ($n = 32$, $r = -0.032$). Subtle variations in experimental design and stimulus delivery could have influenced the PAF–pain relationship. Crucially, the present study did not calibrate the temperature of the PHP model based on participants' thresholds for moderate pain. Consequently, the fixed temperature did not produce a moderately painful stimulus for all participants, in contrast to previous studies that calibrated to a moderately painful stimuli [10]. This discrepancy may account for the correlation observed between PAF and heat pain ratings among only the male participants in our study, as fixed stimuli can create ceiling or floor effects [80]. Previous literature has also acknowledged the potential for sex differences in the PAF–pain relationship [16].

In parallel, we saw no indication of a relationship between PAF and pain ratings during CPA. The introduction of the CPA model, specifically calibrated to a moderate pain threshold, provides further support for the notion that the relationship between PAF and pain is specific to certain pain types [16,27]. Prolonged heat pain was predominantly described as moderate/severe shooting, sharp, and hot, much like chronic neuropathic pain, whereas prolonged pressure pain was predominantly described as mild/moderate throbbing, cramping, and aching in the present study, more closely resembling musculoskeletal pain. Therefore, it is possible that the PAF–pain relationship is specific to neuropathic-like pain [16]. Previous experimental pain literature has suggested that slower PAF is related to higher pain sensitivity for PHP [10], capsaicin heat pain [8,10], and nerve growth factor (NGF) [9] models, while faster PAF has been related to higher pain sensitivity in tonic heat pain [7] and NGF [14]. Here we contribute to this

literature by showing no relationship between baseline PAF and pain sensitivity during the CPA model. Further investigation of the PAF–pain relationship with a variety of prolonged pain models is warranted [12].

3.4 Study limitations and constraints

This study presents opportunities for future research due to certain limitations. First, the dose of nicotine administered was equivalent to one cigarette [81]; however, to enhance the efficacy of this research, exploring higher doses or dosing based on weight could be beneficial. Second, blood or saliva samples were not collected in the present study, therefore it is unclear whether participants absorbed similar amounts of nicotine. Future studies in this area should also be powered to perform sex-disaggregated analyses, as our findings indicate a relationship between baseline PAF and subsequent heat pain intensity only in males, and stronger nicotine modulation of PAF in female participants.

3.5 Conclusion

In this study, we employed a rigorous double-blind, randomised, placebo-controlled design, pre-registered the analysis, and introduced a novel difference score 2W-LCS mediation model to examine the mediating role of changes in PAF on pain while controlling for pre-determined confounders. These methodological choices allowed for a comprehensive investigation into whether PAF plays a mechanistic role in pain sensitivity.

We have shown that, compared to placebo, nicotine gum increases global PAF speed and decreases pain ratings during prolonged heat pain. However, the effects of nicotine on heat pain were not mediated by changes in PAF. Therefore, we find no evidence that PAF is causally related to pain. The implication of this is that changing PAF may not be a useful target for pain modulation, because pain sensitivity may not be dependent on state changes in PAF. However, this is the first study to test modulation of PAF as a mechanism for acute analgesia. More randomised experiments of the effects of nicotine that use larger sample sizes, track the pharmacokinetics of nicotine, whilst reducing mediator measurement error are needed to uncover whether these factors account for the lack of mediation effect seen here.

A growing body of evidence indicates a relationship between PAF and pain, including chronic pain studies [16,23,25–27,82], and experimental pain research from our own [8–13] and other groups [7,14–17]. Alongside validation of its clinical predictive utility [13,83], further research is needed to ascertain the causal nature of the relationship, explore PAF as a potential target for pain modulation, and gain deeper mechanistic insights into the PAF–pain relationship.

4 Methods

4.1 Design overview

The study employed a randomised, double-blind, placebo-controlled, parallel experimental design. Testing sessions were balanced for treatment (i.e. nicotine or placebo gum) and stratified by sex. Individuals were required to attend one 150 minute session. The experimental flow for this study is summarised in **Figure 6**.

4.2 Participants

From June 2021 to March 2022, 62 individuals participated at Neuroscience Research Australia (NeuRA). Inclusion criteria for the study were for participants to be healthy, pain free, non-smoking, and between 18–45 years of age, inclusive.




Figure 6

Timeline of experimental events. Electroencephalography (EEG) data were collected during eyes open and eyes closed resting states before and after each pain assessment. Prolonged pain assessments consisted of cuff pressure algometry (CPA) followed by phasic heat pain (PHP) models, and took place before and after gum chewing.

Non-smokers were defined as individuals who have smoked fewer than 100 cigarettes and/or e-cigarettes in their lifetime and have not smoked over the past 12 months. Exclusion criteria: previous use of nicotine gum; history of neurological, musculoskeletal, cardiovascular, or psychiatric conditions; other major diseases or disorders; current muscle pain; breastfeeding or pregnant; use of opioids, illicit drugs, or excessive alcohol in the past three months; or unable to provide informed consent.

4.3 Ethics approval and consent to participate

The Human Research Ethics Committee (HREC) Executive at the University of New South Wales (UNSW) approved this project (HC190466).

4.4 Experimental protocol

Participants were screened for eligibility by telephone and were asked to refrain from drinking coffee or caffeinated drinks two hours prior to the start of testing, as caffeine may impact nicotine absorption [84 [↗](#), 85 [↗](#)].

After signing informed consent, cool and warmth detection tests were conducted, followed by PHP familiarisation, then CPA calibration. During these introductions the participants were also familiarised with the VAS pain rating.

EEG capture started with the control condition of three cycles of warm temperatures, after which the remaining experimental flow is illustrated in **Figure 6** [↗](#). The first resting state period was recorded, followed by the first pain assessments (i.e. CPA and PHP model), which were immediately followed by the second resting state. EEG recorded during the pain assessments was not analysed for the present article. Then either nicotine or placebo gum was administered with the chew procedure, followed by the third resting state, the second pain assessments, and the fourth resting state. The experiment ended with participants completing the gum chew experience questionnaire and debrief.

4.5 Data collection procedures

Questionnaires

Participants completed a set of questionnaires to assess demographics, medical history, general health, mental health, pain, and sleep. This data was collected electronically and stored using REDcap [86 [↗](#), 87 [↗](#)].

Questionnaires included the following National Institutes of Health common data elements (CDE) for pain biomarkers: Pain Catastrophizing Scale (PCS) [88 [↗](#)]; Brief Pain Inventory (BPI), Pain Severity and 7-item Interference subscales [89 [↗](#), 90 [↗](#)]; SF-8 to assess general health [91 [↗](#)]; Patient Health Questionnaire-2 (PHQ-2) to assess depression [92 [↗](#)]; Generalised Anxiety Disorder Questionnaire-2 (GAD-2) to assess anxiety [93 [↗](#)]; Pennebaker Inventory of Limbic Languidness (PILL) to assess reporting of physical symptoms and sensations [94 [↗](#)]; Tobacco, Alcohol, Prescription medications, and other Substances (TAPS); sleep scale. The sleep scale asked “how would you rate your sleep last night?”, on a scale from 1 (i.e. “poor sleep quality”) to 10 (i.e. “excellent sleep quality”). In addition, a health history form, the Karolinska sleepiness scale (KSS) [95 [↗](#)], Epworth sleepiness scale (ESS) [96 [↗](#)], the perceived stress scale (PSS) [97 [↗](#)], and questions regarding participants current level of weekly physical activity were included.

Electroencephalography

EEG was recorded from 63 active wet electrodes (actiCap, Brain Products GmbH, Germany), embedded in an elastic cap (EASYCAP, GmbH) in accordance with the international 10-10 system. Recordings were referenced online to 'FCz' and the ground electrode was placed on 'FPz'. A sampling rate of 5000 Hz was used and impedance was kept below 25 kOhms throughout testing using electrolyte gel. EEG signal was amplified and digitised using an actiCHamp Plus DC amplifier linked to BrainVision Recorder software (version 1.22.0101, Brain Products GmbH, Gilching, Germany).

For each recording, resting state EEG was obtained during eyes open (three minutes) followed by eyes closed (three minutes). The eyes open recording took place in low lighting while participants rested their gaze on a white fixation cross with a black background displayed on a monitor. The eyes closed recording took place with the lights off. For both recordings participants were asked to rest in a comfortable seated position and try not to fall asleep.

Pain assessment

Two tonic (i.e. prolonged) pain assessments were conducted during the study, a phasic heat pain (PHP) model [10] and a cuff pressure algometry (CPA) model [57,98]. Pain intensity was sampled at 1 Hz during pain stimulation using a visual analogue scale (VAS), with anchors 'no pain' on the left to 'worst pain imaginable' on the right, custom MATLAB (version R2021a) code (source available: <https://osf.io/2yaxz/>). Participants were instructed to press the 'STOP' button on the screen if they became too uncomfortable and wanted to stop the pain assessments.

The Short Form McGill Pain Questionnaire 2 (SF-MPQ-2) [99] was used after each pain model to assess experienced qualities (e.g., throbbing, cramping, burning).

Heat pain

Equipment

Thermal stimuli were applied to the volar surface of the left forearm using a thermal-contact heat stimulator (27 mm diameter Medoc Pathways CHEPS Peltier device, Medoc Advanced Medical Systems Ltd., Ramat Yishai, Israel).

Cool and warmth detection thresholds

The thermode was placed on the volar surface of the left arm at a neutral temperature (32 °C). Participants were instructed to press a button held in their right hand when they sensed a change in temperature. Four areas were marked out by drawing three perpendicular lines equidistant from the elbow crease to 4 cm below the base of the palm. On each trial, the researcher moved through these locations on the forearm in a randomly generated sequence. There were three trials each for warmth (ascending temperatures) and cool (descending temperatures) detection thresholds. Participants were required to consistently detect the warmth and cool transitions in order to continue with the experiment.

Heat pain threshold

Participants were required to press the hand-held button with their right hand the moment they felt any pain as the thermode temperature increased at a rate of 1.5 °C/second. This pain threshold test was conducted three times and an average heat pain threshold was calculated.

Familiarisation

Participants were initially introduced to the PHP model (see below) by receiving two cycles of the heat pain, to ensure they would tolerate the maximum temperature of 46 °C during the experiment and to familiarise participants with using the VAS. If a participant was uncomfortable with receiving 46 °C, the temperature was decreased by 1 °C and the PHP familiarisation was repeated to ensure this temperature was tolerable.

Phasic warmth

Participants experienced three rounds of a phasic warm stimulus. Stimulus trains consisted of a rise phase of 2 °C/s, followed by a 40 second phase where a temperature was held at 36 °C, then a fall phase at a rate of 1 °C/s to reach 32 °C. This neutral temperature was then held for 20 seconds before the cycle repeated three times.

Phasic heat pain (PHP) model

The PHP model consisted of a series of five repetitions of phasic stimuli, each lasting one minute 21 seconds. Stimulus trains consisted of a rise phase of 2 °C/s, followed by a 40 second phase where a temperature was held at 46 °C, then a fall phase at a rate of 1 °C/s to reach 32 °C. This neutral temperature was then held for 20 seconds before the cycle repeated five times. The PHP model lasted six minutes 45 seconds, and participants rated their pain continuously on the VAS. Similar methodology using repetitive-phasic models have shown that this procedure reliably evokes tonic pain and sensitisation in healthy participants [8,10].

Pressure pain

Equipment

Pressure was applied using a standard double-chamber adult arm cuff (length 45cm, width 15cm) placed in the middle of the left lower leg over the head of the gastrocnemius soleus muscle.

Familiarisation and calibration

Participants underwent a pressure cuff calibration. Similar to previous literature [58,60], the pressure was gradually increased manually (30 mmHg/5 seconds) until the participant reported a moderate pain intensity of 4/10 on the VAS and pressure was automatically recorded. This gradual pressure increase was conducted three times with a two minute break between each test, to establish the average pressure required to evoke 4/10 pain for each participant. The maximum pressure limit for this study was 100 kPa (750 mmHg) [61]. This is well within safe limits, as previous studies have used maximums of 180 or 200 kPa without adverse effects [57–59].

Cuff pressure algometry (CPA) model

Pressure was increased manually (30 mmHg/5 seconds) until the individualised pressure was reached, then held constant for four minutes. Participants rated their pain continuously using the VAS.

Gum chewing

Nicotine was administered orally in the form of 4 mg of cinnamon flavoured Nicorette® gum (Johnson & Johnson Inc., Markham, Ontario, Canada); comparable to smoking a single cigarette, this produces a blood concentration of approximately 15-30 mg/ml [81]. The placebo gum was cinnamon flavoured Xyloburst® natural chewing gum, which, other than containing no nicotine,

is of a similar flavour, size, and texture to the nicotine gum. At the end of the experiment, before being debriefed, participants completed a short questionnaire about the gum chewing experience to test perceptual matching between the nicotine and placebo gums.

To promote nicotine absorption, participants rinsed their mouth with a glass of water for 10 seconds prior to receiving the gum, as performed previously [84]. We used a protocol similar to Bowers and colleagues [37], following manufacturer's guidelines of a total chewing time of 25 minutes. Audio cues to bite the gum occurred every 30 seconds for a total of 25 minutes; participants were asked to alternate between the left and right sides of the mouth, and to park the gum between the teeth and cheek between chews. Participants watched a wildlife documentary during the chewing to maintain attention; all participants watched the same documentary to control for its possible effects.

Randomisation and blinding

Participants were randomised in a 1:1 ratio to receive either nicotine gum or placebo gum. The allocation list was created a priori, independently of the primary experimenter, using blocked randomisation based on sex at birth. The allocation was blind to both the participant and experimenter. All participants were told that they were receiving nicotine gum to provide equal expectations. Participants were debriefed at the end of the experiment and asked whether they thought they had been given nicotine, placebo, or if they weren't sure. Participants were unblinded by the independent researcher separately. The primary experimenter remained blinded with dummy variables until completion of analysis.

4.6 Data processing

EEG pre-processing

Blinded preprocessing of de-identified EEG was conducted with custom code in MATLAB 2020a (v.9.8.0.1417392, The MathWorks, Inc., Natick, MA, USA) using EEGLAB 2020.0 [100] and FieldTrip (v.20200607) [101].

Using EEGLAB, for four resting states, each participant's data were downsampled to 500 Hz, filtered between 2 and 100 Hz using a linear finite impulse response (FIR) bandpass filter, and the three minute periods of eyes closed resting state were visually inspected and overtly noisy channels with ≥ 8 signal deviations (e.g., popping, baseline drift, line noise) were removed. The average number of channels removed were 0.94, 0.98, 0.74, and 0.87 (range: 0–4) for the four resting states, respectively. Removed channels were not interpolated. Data from the remaining channels were re-referenced to the common average reference.

Using FieldTrip, data were segmented into 5 second epochs, with no overlap, visually inspected using *ft_databrowser()*, and epochs containing any electrode, muscle, or motion artefacts were removed. From a maximum of 36 epochs (i.e. 3 mins), the average number of remaining epochs was 31.21, 31.33, 32.13, and 31.39 (range: 24–36) for each resting state, respectively. No resting state contained less than two minutes of data [83]. Principal component analysis using the *runica* method was applied to identify and remove components reflecting eye blinks and/or saccades. The average number of components removed per resting state was 1.05, 1.2, 1.1, 1.2 (range: 0–2), respectively.

Quantification of peak alpha frequency (PAF)

Each participant's PAF was estimated for the four eyes closed resting states. FieldTrip was used to calculate the power spectral density in the range of 2–40 Hz for each epoch in 0.2 Hz bins. A Hanning taper was applied to the data prior to calculating spectra to reduce any edge artefacts

[102]. The PAF for each power spectral density was estimated using the centre of gravity (CoG) method [103–107]:

$$\text{CoG} = \frac{\sum_{i=1}^n f_i a_i}{\sum_{i=1}^n a_i} \quad (1)$$

where f_i is the i^{th} frequency bin, n is the number of frequency bins within the frequency window (8–12 Hz or 9–11 Hz), and a_i is the amplitude of the frequency for f_i . This equation states that PAF is the weighted sum of spectral estimates [103]. Global (i.e. average of all electrodes) and a sensorimotor region of interest were used (i.e. average of C3, C1, Cz, C2, and C4). PAF estimates for each participant at each time point were calculated.

The frequency range used to calculate PAF varies in the PAF–pain literature. The narrower 9–11 Hz band reduces the impact of 1/f noise (i.e. trend of higher power at lower frequencies) on the PAF estimations [8,102], however the narrow band may not produce representative PAF values for those with peaks near the lower or upper limits. Therefore, the wider 8–12 Hz band was used as the primary band of interest (Figure 2, plot A). All analyses were repeated with the narrower band and are displayed in Supplementary Material 3.4 and 3.6. Power was calculated using the wider 8–12 Hz band to display alpha on topographical plots.

4.7 Statistical analysis

Statistical analysis was conducted in RStudio (RStudio Team, 2021.9.1.372). A Guideline for Reporting Mediation Analysis (AGReMA) was followed for this article [108] and the analysis plan was pre-registered (<https://osf.io/2yaxz/>).

Mediation analysis

Using a structural equation modelling approach, a two-wave latent change score (2W-LCS) model – recommended by Valente and MacKinnon [62] – was used to assess whether nicotine changed PAF or pain (i.e. hypotheses 1–3).

Prior to modelling, a paired equivalence test satisfied that PAF_{1a} (i.e. pre-gum before the first pain assessment) and PAF_{1b} (i.e. pre-gum after the first pain assessment) were equivalent ($t(60) = 0.90$, $p < .001$), therefore PAF_{1a} was used in the below models.

Latent change score (LCS) specification

Calculating the absolute difference between pre- and post-gum variables can result in regression to the mean [62]. With LCS specification, the second wave of PAF and pain (i.e. post-gum) can be set as a unit-weighted function of pre-gum and a new unobserved change variable (i.e. Δ_{PAF} and Δ_{pain}) to simulate subtracting pre-gum scores from post-gum scores on PAF and pain variables [62].

$$\Delta_{PAF} = \text{PAF}_{2a} - \text{PAF}_{1a} \quad (2)$$

$$\Delta_{pain} = \text{Pain}_2 - \text{Pain}_1 \quad (3)$$

Simulation of the above equations was achieved via the following parameter constraints. Loading on Pain_2 was fixed to one, while the mean and variance of Δ_{pain} were freely estimated. The path from Pain_1 to Pain_2 was fixed to 1, the mean (i.e. intercept) and variance of Pain_2 were constrained to zero, and the mean and variance of Pain_1 were freely estimated. The same approach was taken for Δ_{PAF} . The covariances between PAF_{1a} and Pain_1 were freely estimated.

Two-wave latent change score (2W-LCS) models

The above latent change variables (Equation 2 and Equation 3) can then be used within 2W-LCS models to conduct mediation analysis. Two model variations were constructed to assess total, direct, and indirect effects of nicotine separately for latent change in mean ratings during PHP and CPA as outcomes (Table 4). Models were constructed in R (version 4.2.1) [109] using the lavaan package [110] with maximum likelihood estimation and 1000 bootstraps (seed: 2022) to compute standard errors. The mediation model syntax is available online (<https://osf.io/2yaxz/>).

The ANCOVA-equivalent 2W-LCS model

The first model variation used was the ANCOVA-equivalent model [62], the path diagram is displayed in Figure 7 and the below equations were used (Equation 4 and Equation 5):

$$\Delta_{PAF} \sim i_1 + a_{m2x}Gum + s_{m2m1}PAF_1 + b_{m2y1}Pain_1 + \text{covariates} + e_1 \quad (4)$$

$$\Delta_{pain} \sim i_2 + c'_{y2y1}Gum + s_{y2y1}Pain_1 + b_{y2m1}PAF_1 + b_{y2m2}\Delta_{PAF} + \text{covariates} + e_2 \quad (5)$$

In this model, i denotes the intercept and e denotes error. Both $s_{m2m1}M_1$ and $s_{y2y1}Y_1$ are time-lagged autoregressions referring to change in M and Y due to prior levels of M and Y, respectively. These autoregressions reflect that each variable influences itself over time. The $b_{y2m1}M_1$ and $b_{m2y1}Y_1$ are cross-lagged coupling parameters, which refer to effects of previous levels of M on change in Y and effects of previous levels of Y on change in M. In other words, each variable influences the other variable at the subsequent time point. As displayed in Figure 7, X is predicting constant change in Y via the direct c' -path (Equation 5; c'_{y2y1}) and constant change in M via the a -path (Equation 4; a_{m2x}). Latent change in M is predicting later latent change in Y via the constrained b -path (Equation 5; b_{y2m2}). The indirect effect was assessed by estimating the product of coefficients ab ($a_{m2x}X * b_{y2m2}$). The total effect was assessed by summation of the indirect and direct effects (i.e. $c'_{y2y1} + [a_{m2x}X * b_{y2m2}]$).

Difference score 2W-LCS model

We compared the ANCOVA-equivalent model (Figure 7) to the difference score model (Figure 8); the former adjusts for the effects of pre-gum PAF and pain on post-gum PAF and pain, while the latter assumes those paths are equal to zero [62]. Removal of autoregressive (i.e. $s_{m2m1}M_1$ and $s_{y2y1}Y_1$) and coupling parameters (i.e. $b_{y2m1}M_1$ and $b_{m2y1}Y_1$) produces a simpler unconditional model of change [63, 111]. The path diagram is displayed in Figure 8 and the below equations were used (Equation 6 and Equation 7):

$$\Delta_m \sim i_3 + aGum + \text{covariates} + e_3 \quad (6)$$

$$\Delta_y \sim i_4 + c'Gum + b\Delta_{PAF} + \text{covariates} + e_4 \quad (7)$$

Model fit and comparison

Model fits were compared with χ^2 statistic ($p > 0.05$), comparative fit index (CFI), standardised root mean squared residual (SRMR), and root mean square error of approximation (RMSEA).

Confounding

The intervention–mediator (a -path) and intervention–outcome (c' -path) relationships are unconfounded due to the random allocation of nicotine or placebo gum. For the mediator–outcome (b -path) relationship, potential confounders were chosen by selecting variables measured prior to gum allocation that we assume to be a cause of the mediator, outcome, or both [112].

Model	Intervention	Mediator	Outcome
1.1	Nicotine	Latent Δ PAF	Latent Δ mean heat pain
1.2	Nicotine	Latent Δ PAF	Latent Δ mean pressure pain

Table 4

Overview of mediation models.




Figure 7

Adapted from Valente and MacKinnon [62]. The analysis of covariance (ANCOVA) equivalent pre-test/post-test control group design (two-wave) with latent change score (LCS) specification for the outcome (Y: pain) and mediating (M: PAF) variables. The direct effect of the intervention on the outcome is represented by the red line (c'_{y2x}). The intervention-mediator relationship is represented by a green line (a_{m2x}) from the intervention (i.e. X: nicotine vs. placebo) to the mediator (i.e. Δ_M). The mediator-outcome relationship is represented by another green line (b_{y2m2}) from the mediator (i.e. Δ_M) to the outcome (i.e. Δ_Y). Together the two green lines represent the indirect effect of the intervention on the outcome via the mediator. Time-lagged autoregression paths are represented by S^*_{m2m1} and S^*_{y2y1} . Cross-lagged coupling paths are represented by b_{m2y1} and b_{y2m1} . The covariance between Y and M at baseline is represented by σ_{m1y1} . The potential confounders of the mediator-outcome relationship were measured at baseline and are represented by the blue dashed lines. Note. * = latent; X = intervention (i.e. gum); M = mediator (i.e. PAF); Y = outcome (i.e. pain).




Figure 8

Adapted from Valante and MacKinnon [62]. The difference score model with latent change score specification for the outcome (Y) and mediating (M) variables. The direct effect of the intervention on the outcome is represented by the red line (c'_Δ). The intervention-mediator relationship is represented by a green line (a_{m2x}) from the intervention (i.e. X: nicotine vs. placebo) to the mediator (i.e. Δ_M). The mediator-outcome relationship is represented by another green line (b_Δ) from the mediator (i.e. Δ_M) to the outcome (i.e. Δ_Y). Together the two green lines represent the indirect effect of the intervention on the outcome via the mediator. Cross-lagged coupling paths are constrained to 0 and time-lagged autoregressions are constrained to 1. The covariance between Y and M at baseline is represented by σ_{m1y1} . The potential confounders of the mediator-outcome relationship are represented by the blue dashed lines. *Note.* X = intervention (i.e. gum); M = mediator (i.e. PAF); Y = outcome (i.e. pain).

We assume that the mediator–outcome relationship is unconfounded after adjusting for the pre-determined (Supplementary Material 7.1; [113,114]) minimum sufficient set of observed confounders: sex at birth, depression symptoms, anxiety symptoms, perceived stress, sleep quality, and recent pain (**Figure 7**). Within the model, the variance of each covariate was freely estimated, along with their co-variance with baseline values of PAF and pain.

Assumptions

Multicollinearity assessment (R^2 cut-off of 0.7) did not suggest any covariates requiring removal. Using the *mvn()* function, we found violation of multivariate normality (Mardia skewness = 361.28, $p < .001$; Mardia kurtosis = 2.39, $p = 0.017$) as well as univariate normality for covariates 2, 3, 5, and 6 ($W = 0.60$ – 0.93 , $p < 0.0019$), the impact of which was reduced by use of bootstrapping [115,116]. There was no systematically missing data and only complete datasets were used, incomplete sets were removed by listwise deletion.

Mediation using PROCESS

PROCESS is a statistics package in R for conducting mediation analysis [64], and is frequently used in the literature [117–119]. PROCESS analysis was conducted using an ANCOVA-equivalent model without the LCS specification, as construction of latent variables is not currently possible in this package [64]. Pain and PAF post-gum (i.e. PAF_{2a} and $pain_2$) were used as outcome measures rather than change in each, with PAF_1 and $pain_1$ included alongside the other covariates. The estimates produced by PROCESS were similar to the ANCOVA-equivalent 2W-LCS model in lavaan, and are displayed in the Supplementary Material 7.2.

Cluster-based permutation analysis

An exploratory non-parametric cluster-based permutation analysis [120,121] was conducted to assess where changes in global PAF occurred in sensor space, similar to those conducted by Furman and colleagues [122]. Tests conducted at the single electrode level were thresholded at $p < .01$. If two or more spatially adjacent electrodes passed this threshold, they were grouped into a cluster, and each electrode within a cluster had to be adjacent to at least one other electrode from the overall cluster. Following the formation of clusters, test statistic values were summed across all electrodes within a cluster to obtain a composite test score for that cluster. For each potential cluster, this composite test score was then compared against a null distribution of 1000 generated scores produced by random shuffle of values for the dependent variable across conditions and participants at each electrode of the cluster. If a cluster's composite test statistic surpassed the 99th percentile of the null distribution, that cluster was evaluated as significant.

PAF–pain relationship

To address whether faster sensorimotor or global PAF during pain-free resting states was associated with lower pain ratings during the first PHP and CPA models before gum chewing (i.e. hypothesis 4), correlations were used [7–10].

Bayesian correlations were conducted in R ('BayesFactor' package, default priors) between pain-free baseline 8–12 Hz PAF (i.e. global and sensorimotor) and pain measures (i.e. mean, max, AUC) during each model (i.e. PHP, CPA) prior to gum administration.

Median splits on PAF speed were conducted, and the difference in pain reported between PAF speed groups was assessed by independent t-tests for mean and AUC pain, with Mann Whitney-U test for max PHP pain, due to violation of normality ($W = 0.89$, $p < .001$). Results of median splits are displayed in Supplementary Material 6.1.

References

- [1] Tunks ER, Crook J, Weir R (2008) **Epidemiology of chronic pain with psychological comorbidity: Prevalence, risk, course, and prognosis** *The Canadian Journal of Psychiatry* **53**:224–34 <https://doi.org/10.1177/070674370805300403>
- [2] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. (2012) **Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: A systematic analysis for the global burden of disease study 2010** *The Lancet* **380**:2163–96 [https://doi.org/10.1016/S0140-6736\(12\)61729-2](https://doi.org/10.1016/S0140-6736(12)61729-2)
- [3] Mann R, Schaefer C, Sadosky A, Bergstrom F, Baik R, Parsons B, et al. (2013) **Burden of spinal cord injury-related neuropathic pain in the united states: Retrospective chart review and cross-sectional survey** *Spinal Cord* **51**:564–70 <https://doi.org/10.1038/sc.2013.34>
- [4] Van Der Miesen MM, Lindquist MA, Wager TD (2019) **Neuroimaging-based biomarkers for pain: State of the field and current directions** *Pain Reports* **4** <https://doi.org/10.1097/PR9.0000000000000751>
- [5] Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, et al. (2020) **Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: Challenges and opportunities** *Nature Reviews Neurology* **16**:381–400 <https://doi.org/10.1038/s41582-020-0362-2>
- [6] Tracey I (2021) **Neuroimaging enters the pain biomarker arena** *Science Translational Medicine* **13**
- [7] Nir RR, Sinai A, Raz E, Sprecher E, Yarnitsky D (2010) **Pain assessment by continuous EEG: Association between subjective perception of tonic pain and peak frequency of alpha oscillations during stimulation and at rest** *Brain Research* **1344**:77–86 <https://doi.org/10.1016/j.brainres.2010.05.004>
- [8] Furman AJ, Meeker TJ, Rietschel JC, Yoo S, Muthulingam J, Prokhorenko M, et al. (2018) **Cerebral peak alpha frequency predicts individual differences in pain sensitivity** *Neuroimage* **167**:203–10 <https://doi.org/10.1016/j.neuroimage.2017.11.042>
- [9] Furman AJ, Thapa T, Summers SJ, Cavaleri R, Fogarty JS, Steiner GZ, et al. (2019) **Cerebral peak alpha frequency reflects average pain severity in a human model of sustained, musculoskeletal pain** *Journal of Neurophysiology* **122**:1784–93 <https://doi.org/10.1152/jn.00279.2019>
- [10] Furman AJ, Prokhorenko M, Keaser ML, Zhang J, Chen S, Mazaheri A, et al. (2020) **Sensorimotor Peak Alpha Frequency Is a Reliable Biomarker of Prolonged Pain Sensitivity** *Cerebral Cortex* :1–14 <https://doi.org/10.1093/cercor/bhaa124>
- [11] Millard SK, Furman AJ, Kerr A, Seminowicz DA, Gao F, Naidu BV, et al. (2022) **Predicting postoperative pain in lung cancer patients using preoperative peak alpha frequency** *British Journal of Anaesthesia* **128**:e346–8 <https://doi.org/10.1016/j.bja.2022.03.006>

- [12] Mazaheri A, Seminowicz DA, Furman AJ (2022) **Peak alpha frequency as a candidate biomarker of pain sensitivity: The importance of distinguishing slow from slowing** *NeuroImage* **262** <https://doi.org/10.1016/j.neuroimage.2022.119560>
- [13] Seminowicz DA, Bilski K, Chowdhury NS, Skippen P, Millard SK, Chiang AK, et al. (2020) **A novel cortical biomarker signature for predicting pain sensitivity: Protocol for the PREDICT longitudinal analytical validation study** *Pain Reports* **5** <https://doi.org/10.1097/PR9.0000000000000833>
- [14] De Martino E, Gregoret L, Zandalasini M, Graven-Nielsen T (2021) **Slowing in peak alpha frequency recorded after experimentally-induced muscle pain is not significantly different between high and low pain-sensitive subjects** *The Journal of Pain* **22**:1722–32 <https://doi.org/10.1016/j.jpain.2021.06.004>
- [15] McLain NJ, Yani MS, Kutch JJ (2022) **Analytic consistency and neural correlates of peak alpha frequency in the study of pain** *Journal of Neuroscience Methods* **368** <https://doi.org/10.1016/j.jneumeth.2021.109460>
- [16] Fauchon C, Kim JA, El-Sayed R, Osborne NR, Rogachov A, Cheng JC, et al. (2022) **A hidden markov model reveals magnetoencephalography spectral frequency-specific abnormalities of brain state power and phase-coupling in neuropathic pain** *Communications Biology* **5**:1–12 <https://doi.org/10.1038/s42003-022-03967-9>
- [17] Valentini E, Halder S, McInnerney D, Cooke J, Gyimes IL, Romei V (2022) **Assessing the specificity of the relationship between brain alpha oscillations and tonic pain** *NeuroImage* **255** <https://doi.org/10.1016/j.neuroimage.2022.119143>
- [18] Jensen O, Mazaheri A (2010) **Shaping functional architecture by oscillatory alpha activity: Gating by inhibition** *Frontiers in Human Neuroscience* **4** <https://doi.org/10.3389/fnhum.2010.00186>
- [19] VanRullen R (2016) **Perceptual cycles** *Trends in Cognitive Sciences* **20**:723–35 <https://doi.org/10.1016/j.tics.2016.07.006>
- [20] Cecere R, Rees G, Romei V (2015) **Individual differences in alpha frequency drive crossmodal illusory perception** *Current Biology* **25**:231–5 <https://doi.org/10.1016/j.cub.2014.11.034>
- [21] Samaha J, Postle BR (2015) **The speed of alpha-band oscillations predicts the temporal resolution of visual perception** *Current Biology* **25**:2985–90 <https://doi.org/10.1016/j.cub.2015.10.007>
- [22] Wutz A, Melcher D, Samaha J (2018) **Frequency modulation of neural oscillations according to visual task demands** *Proceedings of the National Academy of Sciences* **115**:1346–51 <https://doi.org/10.1073/pnas.1713318115>
- [23] Sarntinoranont J, Stern J, Aufenberg C, Rousson V, Jeanmonod D (2006) **Increased EEG power and slowed dominant frequency in patients with neurogenic pain** *Brain* **129**:55–64 <https://doi.org/10.1093/brain/awh631>
- [24] De Vries M, Wilder-Smith OH, Jongsma ML, Broeke EN van den, Arns M, Van Goor H, et al. (2013) **Altered resting state EEG in chronic pancreatitis patients: Toward a marker for chronic pain** *Journal of Pain Research* :815–24 <https://doi.org/10.2147/JPR.S5>

- [25] Sufianov A, Shapkin A, Sufianova G, Elishev V, Barashin D, Berdichevskii V, et al. (2014) **Functional and metabolic changes in the brain in neuropathic pain syndrome against the background of chronic epidural electrostimulation of the spinal cord** *Bulletin of Experimental Biology and Medicine* **157**:462–5 <https://doi.org/0007-4888/14/1574-0462>
- [26] Lim M, Kim JS, Kim DJ, Chung CK (2016) **Increased low-and high-frequency oscillatory activity in the prefrontal cortex of fibromyalgia patients** *Frontiers in Human Neuroscience* **10**
- [27] Zebhauser PT, Hohn VD, Ploner M (2023) **Resting-state electroencephalography and magnetoencephalography as biomarkers of chronic pain: A systematic review** *Pain* **164** <https://doi.org/10.1097/j.pain.0000000000002825>
- [28] Capotosto P, Babiloni C, Romani GL, Corbetta M (2014) **Resting-state modulation of alpha rhythms by interference with angular gyrus activity** *Journal of Cognitive Neuroscience* **26**:107–19 https://doi.org/10.1162/jocn_a_00460
- [29] Ronconi L, Melcher D, Junghöfer M, Wolters CH, Busch NA (2020) **Testing the effect of tACS over parietal cortex in modulating endogenous alpha rhythm and temporal integration windows in visual perception** *European Journal of Neuroscience* <https://doi.org/10.1111/ejn.15017>
- [30] Sato G, Osumi M, Nobusako S, Morioka S (2021) **The effects of transcranial direct current stimulation combined with aerobic exercise on pain thresholds and electroencephalography in healthy adults** *Pain Medicine* **22**:2057–67 <https://doi.org/10.1093/pm/pnab037>
- [31] Gutmann B, Mierau A, Hülsdünker T, Hildebrand C, Przyklenk A, Hollmann W, et al. (2015) **Effects of physical exercise on individual resting state EEG alpha peak frequency** *Neural Plasticity* **2015** <https://doi.org/10.1155/2015/717312>
- [32] Gutmann B, Huelsduenker T, Mierau J, Strueder HK, Mierau A (2018) **Exercise-induced changes in EEG alpha power depend on frequency band definition mode** *Neuroscience Letters* **662**:271–5 <https://doi.org/10.1016/j.neulet.2017.10.033>
- [33] Gramkow MH, Hasselbalch SG, Waldemar G, Frederiksen KS (2020) **Resting state EEG in exercise intervention studies: A systematic review of effects and methods** *Frontiers in Human Neuroscience* **14** <https://doi.org/10.3389/fnhum.2020.00155>
- [34] Webster K, Ro T (2020) **Visual modulation of resting state α oscillations** *Eneuro* **7** <https://doi.org/10.1523/ENEURO.0268-19.2019>
- [35] Benedetto A, Lozano-Soldevilla D, VanRullen R (2018) **Different responses of spontaneous and stimulus-related alpha activity to ambient luminance changes** *European Journal of Neuroscience* **48**:2599–608 <https://doi.org/10.1111/ejn.13791>
- [36] Rodriguez-Larios J, Alaerts K (2019) **Tracking transient changes in the neural frequency architecture: Harmonic relationships between theta and alpha peaks facilitate cognitive performance** *Journal of Neuroscience* **39**:6291–8 <https://doi.org/10.1523/JNEUROSCI.2919-18.2019>
- [37] Bowers H, Smith D, De La Salle S, Choueiry J, Impey D, Philippe T, et al. (2015) **COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers. Genes** *Brain and Behavior* **14**:466–76 <https://doi.org/10.1111/gbb.12226>

- [38] Pickworth WB, Herning RI, Henningfield JE (1986) **Electroencephalographic effects of nicotine chewing gum in humans** *Pharmacology Biochemistry and Behavior* **25**:879–82 [https://doi.org/10.1016/0091-3057\(86\)90401-6](https://doi.org/10.1016/0091-3057(86)90401-6)
- [39] Pickworth WB, Herning RI, Henningfield JE (1988) **Mecamylamine reduces some EEG effects of nicotine chewing gum in humans** *Pharmacology, Biochemistry, and Behavior* **30**:149–53 [https://doi.org/10.1016/0091-3057\(88\)90438-8](https://doi.org/10.1016/0091-3057(88)90438-8)
- [40] Lambiase M, Serra C (1957) **Fumo e sistema nervosa 1. Modificanzione della' attivita electric corticale da fumo.** *Acta Neurol (Italy)* **12**:475–93
- [41] Golding J (1988) **Effects of cigarette smoking on resting EEG, visual evoked potentials and photic driving** *Pharmacology Biochemistry and Behavior* **29**:23–32 [https://doi.org/10.1016/0091-3057\(88\)90268-7](https://doi.org/10.1016/0091-3057(88)90268-7)
- [42] Knott VJ (1988) **Dynamic EEG changes during cigarette smoking** *Neuropsychobiology* **19**:54–60 <https://doi.org/10.1159/000118434>
- [43] Michel C, Hasenfratz M, Nil R, Bättig K (1988) **Cardiovascular, electrocortical, and behavioral effects of nicotine chewing gum** *Klinische Wochenschrift* **66**:72–9
- [44] Lindgren M, Molander L, Verbaan C, Lunell E, Rosén I (1999) **Electroencephalo-graphic effects of intravenous nicotine—a dose-response study** *Psychopharmacology* **145**:342–50 <https://doi.org/10.1007/s002130051067>
- [45] Domino EF (2001) **Nicotine and tobacco dependence: Normalization or stimulation?** *Alcohol* **24**:83–6 [https://doi.org/10.1016/S0741-8329\(01\)00124-0](https://doi.org/10.1016/S0741-8329(01)00124-0)
- [46] Foulds J, McSorley K, Sneddon J, Feyerabend C, Jarvis MJ, Russell MA (1994) **Effect of subcutaneous nicotine injections on EEG alpha frequency in nonsmokers: A placebo-controlled pilot study** *Psychopharmacology* **115**:163–6 <https://doi.org/10.1007/BF02244767>
- [47] Harkrider AW, Champlin CA (2001) **Acute effect of nicotine on non-smokers: III. LLRs and EEGs** *Hearing Research* **160**:99–110 [https://doi.org/10.1016/S0378-5955\(01\)00347-1](https://doi.org/10.1016/S0378-5955(01)00347-1)
- [48] Nakajima M, Al'Absi M (2014) **Nicotine withdrawal and stress-induced changes in pain sensitivity: A cross-sectional investigation between abstinent smokers and nonsmokers** *Psychophysiology* **51**:1015–22 <https://doi.org/10.1111/psyp.12241>
- [49] Ditre JW, Heckman BW, Zale EL, Kosiba JD, Maisto SA (2016) **Acute analgesic effects of nicotine and tobacco in humans: A meta-analysis** *Pain* **157** <https://doi.org/10.1097/j.pain.0000000000000572>
- [50] Ditre JW, Zale EL, LaRowe LR, Kosiba JD, De Vita MJ (2018) **Nicotine deprivation increases pain intensity, neurogenic inflammation, and mechanical hyperalgesia among daily tobacco smokers** *Journal of Abnormal Psychology* **127** <https://doi.org/10.1037/abn0000353>
- [51] Powers JM, LaRowe LR, Garey L, Zvolensky MJ, Ditre JW (2020) **Pain intensity, e-cigarette dependence, and cessation-related outcomes: The moderating role of pain-related anxiety** *Addictive Behaviors* **111** <https://doi.org/10.1016/j.addbeh.2020.106548>
- [52] Robinson CL, Kim RS, Li M, Ruan QZ, Surapaneni S, Jones M, et al. (2022) **The impact of smoking on the development and severity of chronic pain** *Current Pain and Headache Reports* **26**:575–81 <https://doi.org/10.1007/s11916-022-01060-8>

- [53] Schmidt S, Naranjo JR, Brenneisen C, Gundlach J, Schultz C, Kaube H, et al. (2012) **Pain ratings, psychological functioning and quantitative EEG in a controlled study of chronic back pain patients** *PLoS One* **7** <https://doi.org/10.1371/journal.pone.0031138>
- [54] Dinh ST, Nickel MM, Tiemann L, May ES, Heitmann H, Hohn VD, et al. (2019) **Brain dysfunction in chronic pain patients assessed by resting-state electroencephalography** *Pain* **160** <https://doi.org/10.1097/j.pain.0000000000001666>
- [55] Broeke EN van den, Wilder-Smith OH, Goor H van, Vissers KC, Rijn CM van (2013) **Patients with persistent pain after breast cancer treatment show enhanced alpha activity in spontaneous EEG** *Pain Medicine* **14**:1893–9 <https://doi.org/10.1111/pme.12216>
- [56] Witjes B, Baillet S, Roy M, Oostenveld R, Huygen FJ, Vos CC de (2021) **Magnetoencephalography reveals increased slow-to-fast alpha power ratios in patients with chronic pain** *Pain Reports* **6** <https://doi.org/10.1097/PR9.0000000000000928>
- [57] Polianskis R, Graven-Nielsen T, Arendt-Nielsen L (2001) **Computer-controlled pneumatic pressure algometry - a new technique for quantitative sensory testing** *European Journal of Pain* **5**:267–77 <https://doi.org/10.1053/eujp.2001.0245>
- [58] Polianskis R, Graven-Nielsen T, Arendt-Nielsen L (2002) **Spatial and temporal aspects of deep tissue pain assessed by cuff algometry** *Pain* **100**:19–26 [https://doi.org/10.1016/S0304-3959\(02\)00162-8](https://doi.org/10.1016/S0304-3959(02)00162-8)
- [59] Polianskis R, Graven-Nielsen T, Arendt-Nielsen L (2002) **Modality-specific facilitation and adaptation to painful tonic stimulation in humans** *European Journal of Pain* **6**:475–84 [https://doi.org/10.1016/S1090-3801\(02\)00058-7](https://doi.org/10.1016/S1090-3801(02)00058-7)
- [60] Kim J, Loggia ML, Edwards RR, Wasan AD, Gollub RL, Napadow V (2013) **Sustained deep-tissue pain alters functional brain connectivity** *Pain* **154**:1343–51 <https://doi.org/10.1016/j.pain.2013.04.016>
- [61] Lindskou TA, Christensen SW, Graven-Nielsen T (2017) **Cuff algometry for estimation of hyperalgesia and pain summation** *Pain Medicine (United States)* **18**:468–76 <https://doi.org/10.1093/pm/pnw168>
- [62] Valente MJ, MacKinnon DP (2017) **Comparing models of change to estimate the mediated effect in the pretest–posttest control group design** *Structural Equation Modeling: A Multidisciplinary Journal* **24**:428–50 <https://doi.org/10.1080/10705511.2016.1274657>
- [63] Valente MJ, Georgeson A, Gonzalez O (2021) **Clarifying the implicit assumptions of two-wave mediation models via the latent change score specification: An evaluation of model fit indices** *Frontiers in Psychology* **12** <https://doi.org/10.3389/fpsyg.2021.709198>
- [64] Hayes AF (2022) **Introduction to mediation, moderation, and conditional process analysis: A regression-based approach**
- [65] Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. (2012) **CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials** *International Journal of Surgery* **10**:28–55 <https://doi.org/10.1016/j.ijsu.2011.10.001>
- [66] Pijls BG (2022) **The table i fallacy: P values in baseline tables of randomized controlled trials** *JBJS* **104** <https://doi.org/10.2106/JBJS.21.01166>

- [67] Polianskis R, Graven-Nielsen T, Arendt-Nielsen L (2002) **Pressure-pain function in desensitized and hypersensitized muscle and skin assessed by cuff algometry** *The Journal of Pain* **3**:28–37 <https://doi.org/10.1054/jpai.2002.27140>
- [68] Buczek Y, Le A, Wang A, Stewart J, Shaham Y (1999) **Stress reinstates nicotine seeking but not sucrose solution seeking in rats** *Psychopharmacology* **144**:183–8 <https://doi.org/10.1007/s002130050992>
- [69] Woodcock EA, Stanley JA, Diwadkar VA, Khatib D, Greenwald MK (2020) **A neurobiological correlate of stress-induced nicotine-seeking behavior among cigarette smokers** *Addiction Biology* **25** <https://doi.org/10.1111/adb.12819>
- [70] Melzack R (1999) **Melzack R. Pain and stress: A new perspective. 1999.** *Pain and stress: A new perspective*
- [71] Hannibal KE, Bishop MD (2014) **Chronic stress, cortisol dysfunction, and pain: A psychoneuroendocrine rationale for stress management in pain rehabilitation** *Physical Therapy* **94**:1816–25 <https://doi.org/10.2522/ptj.20130597>
- [72] Sawicki CM, Humeidan ML, Sheridan JF (2021) **Neuroimmune interactions in pain and stress: An interdisciplinary approach** *The Neuroscientist* **27**:113–28 <https://doi.org/10.1177/1073858420914747>
- [73] Dunn G, Emsley R, Liu H, Landau S, Green J, White I, et al. (2015) **Evaluation and validation of social and psychological markers in randomised trials of complex interventions in mental health: A methodological research programme.** *Health Technology Assessment (Winchester England)* **19**:1–116 <https://doi.org/10.3310/hta19930>
- [74] Krus DJ, Wilkinson SM (1986) **Demonstration of properties of a suppressor variable** *Behavior Research Methods, Instruments, & Computers* **18**:21–4 <https://doi.org/10.3758/BF03200988>
- [75] Cheung GW, Lau RS (2008) **Testing mediation and suppression effects of latent variables: Bootstrapping with structural equation models** *Organizational Research Methods* **11**:296–325
- [76] Ditre JW, Brandon TH, Zale EL, Meagher MM (2015) **Pain, nicotine, and smoking: Research findings and mechanistic considerations** *Psychological Bulletin* **137**:1065–93 <https://doi.org/10.1037/a0025544>
- [77] Herrmann CS, Rach S, Neuling T, Strüber D (2013) **Transcranial alternating current stimulation: A review of the underlying mechanisms and modulation of cognitive processes** *Frontiers in Human Neuroscience* **7** <https://doi.org/10.3389/fnhum.2013.00279>
- [78] Ploner M, Sorg C, Gross J (2017) **Brain rhythms of pain** *Trends in Cognitive Sciences* **21**:100–10 <https://doi.org/10.1016/j.tics.2016.12.001>
- [79] Kim JA, Davis KD (2021) **Neural oscillations: Understanding a neural code of pain** *The Neuroscientist* **27**:544–70 <https://doi.org/10.1177/1073858420958629>
- [80] Adamczyk WM, Szikszay TM, Nahman-Averbuch H, Skalski J, Nastaj J, Gouverneur P, et al. (2022) **To calibrate or not to calibrate? A methodological dilemma in experimental pain research** *The Journal of Pain* **23**:1823–32 <https://doi.org/10.1016/j.jpain.2022.07.007>

- [81] Meyhöfer I, Kasparbauer A-M, Steffens M, Ettinger U (2019) **Effects of nicotine on smooth pursuit eye movements in healthy non-smokers** *Psychopharmacology* **236**:2259–71 <https://doi.org/10.1007/s00213-019-05223-1>
- [82] Vries M de, Wilder-Smith OHG, Jongsma MLA, Broeke EN van den, Arns M, Goor H van, et al. (2013) **Altered resting state EEG in chronic pancreatitis patients: Toward a marker for chronic pain** *Journal of Pain Research* **6**:815–24 <https://doi.org/10.2147/JPR.S50919>
- [83] Chowdhury NS, Skippen P, Si E, Chiang AK, Millard SK, Furman AJ, et al. (2023) **The reliability of two prospective cortical biomarkers for pain: EEG peak alpha frequency and TMS corticomotor excitability** *Journal of Neuroscience Methods* **385** <https://doi.org/10.1016/j.jneumeth.2022.109766>
- [84] Henningfield JE, Radzius A, Cooper TM, Clayton RR (1990) **Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum** *JAMA: The Journal of the American Medical Association* **264**:1560–4 <https://doi.org/10.1001/jama.1990.03450120072032>
- [85] Blank MD, Kleykamp BA, Jennings JM, Eissenberg T (2007) **Caffeine's influence on nicotine's effects in nonsmokers** *American Journal of Health Behavior* **31**:473–83 <https://doi.org/10.5993/AJHB.31.5.3>
- [86] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) **Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support** *Journal of Biomedical Informatics* **42**:377–81 <https://doi.org/10.1016/j.jbi.2008.08.010>
- [87] Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. (2019) **The REDCap consortium: Building an international community of software platform partners** *Journal of Biomedical Informatics* **95** <https://doi.org/10.1016/j.jbi.2019.103208>
- [88] Sullivan MJL, Bishop SR, Pivik J (1995) **The pain catastrophizing scale: Development and validation** *Psychological Assessment* **7**:524–32 <https://doi.org/10.1037/1040-3590.7.4.524>
- [89] Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS (2004) **Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain** *The Clinical Journal of Pain* **20**:309–18
- [90] Tan G, Jensen MP, Thornby JI, Shanti BF (2004) **Validation of the brief pain inventory for chronic nonmalignant pain** *The Journal of Pain* **5**:133–7 <https://doi.org/10.1016/j.jpain.2003.12.005>
- [91] Ware J, Dewey J, Gandek B (2001) **Ware J, Dewey J, Gandek B. How to score and interpret single-item health status measures: A manual for users of the SF-8 health survey. 2001. How to score and interpret single-item health status measures: A manual for users of the SF-8 health survey**
- [92] Kroenke K, Spitzer R, Williams J (2003) **The patient health questionnaire-2 : Validity of a two-item depression screener author** *Medical Care* **41**:1284–92
- [93] Kroenke K, Spitzer R, Williams J, Monahan P, Lowe B (2007) **Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection** *Annals of Internal Medicine* **146**:317–25 <https://doi.org/10.7326/0003-4819-159-10-201311190-00012>

- [94] Pennebaker J (1982) **The Pennebaker inventory of limbic languidness (the PILL)** *The psychology of physical symptoms*
- [95] Shahid A, Wilkinson K, Marcu S, Shapiro CM (2012) **Karolinska sleepiness scale (KSS). STOP, THAT and one hundred other sleep scales** *Springer Science+Business Media* :1–406 https://doi.org/10.1007/978-1-4419-9893-4_47
- [96] Johns MW (1991) **A new method for measuring daytime sleepiness: The epworth sleepiness scale** *Sleep* **14**:540–5 <https://doi.org/10.1093/sleep/14.6.540>
- [97] Cohen S (1994) **Cohen S. Perceived stress scale (PSS). 1994. 10.1007/978-1-4614-6439-6_773-2. Perceived stress scale (PSS)** https://doi.org/10.1007/978-1-4614-6439-6_773-2
- [98] Abrecht CR, Cornelius M, Wu A, Jamison RN, Janfaza D, Urman RD, et al. (2019) **Prediction of pain and opioid utilization in the perioperative period in patients undergoing primary knee arthroplasty: Psychophysical and psychosocial factors** *Pain Medicine* **20**:161–71 <https://doi.org/10.1093/pm/pny020>
- [99] Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, et al. (2009) **Development and initial validation of an expanded and revised version of the short-form McGill pain questionnaire (SF-MPQ-2)** *PAIN®* **144**:35–42
- [100] Delorme A, Makeig S (2004) **EEGLAB: An open source toolbox for analysis of singletrial EEG dynamics** *Journal of Neuroscience Methods* **134**:9–21 <https://doi.org/10.1016/j.jneumeth.2003.10.009>
- [101] Oostenveld R, Fries P, Maris E, Schoffelen JM (2011) **FieldTrip: Open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data** *Computational Intelligence and Neuroscience* <https://doi.org/10.1155/2011/156869>
- [102] Mazaheri A, Schouwenburg MR van, Dimitrijevic A, Denys D, Cools R, Jensen O (2014) **Region-specific modulations in oscillatory alpha activity serve to facilitate processing in the visual and auditory modalities** *NeuroImage* **87**:356–62 <https://doi.org/10.1016/j.neuroimage.2013.10.052>
- [103] Klimesch W (1999) **EEG alpha and theta oscillations reflect cognitive and memory performance: A review and analysis** *Brain Research Reviews* **29**:169–95 [https://doi.org/10.1016/S0165-0173\(98\)00056-3](https://doi.org/10.1016/S0165-0173(98)00056-3)
- [104] Jann K, Koenig T, Dierks T, Boesch C, Federspiel A (2010) **Association of individual resting state EEG alpha frequency and cerebral blood flow** *Neuroimage* **51**:365–72 <https://doi.org/10.1016/j.neuroimage.2010.02.024>
- [105] Jann K, Federspiel A, Giezendanner S, Andreotti J, Kottlow M, Dierks T, et al. (2012) **Linking brain connectivity across different time scales with electroencephalogram, functional magnetic resonance imaging, and diffusion tensor imaging** *Brain Connectivity* **2**:11–20 <https://doi.org/10.1089/brain.2011.0063>
- [106] Klimesch W, Schimke H, Pfurtscheller G (1993) **Alpha frequency, cognitive load and memory performance** *Brain Connectivity* **5**:241–51 <https://doi.org/10.1007/BF01128991>
- [107] Brötzner CP, Klimesch W, Doppelmayr M, Zauner A, Kerschbaum HH (2014) **Resting state alpha frequency is associated with menstrual cycle phase, estradiol and use of oral contraceptives** *Brain Research* **1577**:36–44 <https://doi.org/10.1016/j.brainres.2014.06.034>

- [108] Cashin AG, McAuley JH, Lee H (2022) **A reporting guideline for randomized trials and observational studies using mediation analysis: AGReMA** *Nature Medicine* **28**:432–4 <https://doi.org/10.1038/s41591-021-01674-2>
- [109] R Core Team (2020) **R: A language and environment for statistical computing**
- [110] Rosseel Y (2014) **Rosseel Y. The lavaan tutorial. Department of Data Analysis: Ghent University 2014.** <https://lavaan.ugent.be/tutorial/>.
- [111] McArdle JJ (2009) **Latent variable modeling of differences and changes with longitudinal data** *Annual Review of Psychology* **60**:577–605 <https://doi.org/10.1146/annurev.psych.60.110707.163612>
- [112] VanderWeele TJ (2019) **Principles of confounder selection** *European Journal of Epidemiology* **34**:211–9 <https://doi.org/10.1007/s10654-019-00494-6>
- [113] Textor J, Van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT (2016) **Robust causal inference using directed acyclic graphs: The r package “dagitty.”** *International Journal of Epidemiology* **45**:1887–94 <https://doi.org/10.1093/ije/dyw341>
- [114] Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, et al. (2019) **Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals** *Annals of the American Thoracic Society* **16**:22–8 <https://doi.org/10.1513/AnnalsATS.201808-564PS>
- [115] Kaplan D (2008) **Structural equation modeling: Foundations and extensions**
- [116] Wulandari D, Sutrisno S, Nirwana MB (2021) **Mardia’s skewness and kurtosis for assessing normality assumption in multivariate regression** *Enthusiastic: International Journal of Applied Statistics and Data Science* :1–6 <https://doi.org/10.20885/enthusiastic.vol1.iss1.art1>
- [117] Morin L, Grégoire S, Lachance L (2021) **Processes of change within acceptance and commitment therapy for university students: Preliminary evidence from a randomized controlled trial** *Journal of American College Health* **69**:592–601 <https://doi.org/10.1080/07448481.2019.1705828>
- [118] Jensen MP, Hakimian S, Ehde DM, Day MA, Pettet MW, Yoshino A, et al. (2021) **Pain-related beliefs, cognitive processes, and electroencephalography band power as predictors and mediators of the effects of psychological chronic pain interventions** *Pain* **162**:2036–50 <https://doi.org/10.1097/j.pain.0000000000002201>
- [119] Irwin MR, Olmstead R, Bjurstrom MF, Finan PH, Smith MT (2022) **Sleep disruption and activation of cellular inflammation mediate heightened pain sensitivity: A randomized clinical trial** *Pain* :10–1097 <https://doi.org/10.1097/j.pain.0000000000002811>
- [120] Maris E, Oostenveld R (2007) **Nonparametric statistical testing of EEG-and MEGdata** *Journal of Neuroscience Methods* **164**:177–90 <https://doi.org/10.1016/j.jneumeth.2007.03.024>
- [121] Pernet CR, Latinus M, Nichols T, Rousselet G (2015) **Cluster-based computational methods for mass univariate analyses of event-related brain potentials/fields: A simulation study** *Journal of Neuroscience Methods* **250**:85–93 <https://doi.org/10.1016/j.jneumeth.2014.08.003>

Article and author information

Samantha K. Millard

Faculty of Medicine, Wallace Wurth Building, University of New South Wales (UNSW), Sydney, NSW 2052, Australia, Centre for Pain IMPACT, Neuroscience Research Australia (NeuRA), 139 Barker Street, Randwick, Sydney, NSW 2031, Australia
ORCID iD: [0000-0003-1409-8179](https://orcid.org/0000-0003-1409-8179)

Alan K.I. Chiang

Faculty of Medicine, Wallace Wurth Building, University of New South Wales (UNSW), Sydney, NSW 2052, Australia, Centre for Pain IMPACT, Neuroscience Research Australia (NeuRA), 139 Barker Street, Randwick, Sydney, NSW 2031, Australia
ORCID iD: [0000-0002-9156-0534](https://orcid.org/0000-0002-9156-0534)

Peter Humburg

Mark Wainwright Analytical Centre, Biological Sciences South Building, University of New South Wales (UNSW), Sydney, NSW 2052, Australia
ORCID iD: [0000-0002-3331-6496](https://orcid.org/0000-0002-3331-6496)

Nahian Chowdhury

Faculty of Medicine, Wallace Wurth Building, University of New South Wales (UNSW), Sydney, NSW 2052, Australia, Centre for Pain IMPACT, Neuroscience Research Australia (NeuRA), 139 Barker Street, Randwick, Sydney, NSW 2031, Australia
ORCID iD: [0000-0001-6357-0746](https://orcid.org/0000-0001-6357-0746)

Raafay Rehan

Faculty of Medicine, Wallace Wurth Building, University of New South Wales (UNSW), Sydney, NSW 2052, Australia, Centre for Pain IMPACT, Neuroscience Research Australia (NeuRA), 139 Barker Street, Randwick, Sydney, NSW 2031, Australia

Andrew J. Furman

Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA, Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD 21201, USA, Center to Advance Chronic Pain Research, University of Maryland Baltimore, Baltimore, MD 21201, USA
ORCID iD: [0000-0001-8055-9610](https://orcid.org/0000-0001-8055-9610)

Ali Mazaheri

School of Psychology, University of Birmingham, Birmingham, B15 2TT, UK, Centre for Human Brain Health (CHBH), University of Birmingham, Birmingham, B15 2TT, UK
ORCID iD: [0000-0001-5732-7555](https://orcid.org/0000-0001-5732-7555)

Siobhan M. Schabrun

Centre for Pain IMPACT, Neuroscience Research Australia (NeuRA), 139 Barker Street, Randwick, Sydney, NSW 2031, Australia, The Gray Centre for Mobility and Activity, Parkwood Institute, London, Ontario, Canada, School of Physical Therapy, University of Western Ontario, London, Ontario, Canada
ORCID iD: [0000-0002-9083-3107](https://orcid.org/0000-0002-9083-3107)

David A. Seminowicz

Centre for Pain IMPACT, Neuroscience Research Australia (NeuRA), 139 Barker Street, Randwick, Sydney, NSW 2031, Australia, Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD 21201, USA, Center to Advance Chronic Pain Research, University of Maryland Baltimore, Baltimore, MD 21201, USA, Department of Medical Biophysics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada
ORCID iD: [0000-0003-3111-3756](https://orcid.org/0000-0003-3111-3756)

Copyright

© 2023, Millard et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

José Biurrun Manresa

National Scientific and Technical Research Council (CONICET), National University of Entre Ríos (UNER), Argentina

Senior Editor

Christian Büchel

University Medical Center Hamburg-Eppendorf, Germany

Reviewer #1 (Public Review):**Summary:**

In this study, Millard and colleagues investigated if the analgesic effect of nicotine on pain sensitivity, assessed with two pain models, is mediated by Peak Alpha Frequency (PAF) recorded with resting state EEG. The authors found indeed that nicotine (4 mg, gum) reduced pain ratings during phasic heat pain but not cuff pressor algometry compared to placebo conditions. Nicotine also increased PAF (globally). However, mediation analysis revealed that the reduction in pain ratings elicited by the phasic heat pain after taking nicotine was not mediated by the changes in PAF. Also, the authors only partially replicated the correlation between PAF and pain sensitivity at baseline (before nicotine treatment). At the group-level no correlation was found, but an exploratory analysis showed that the negative correlation (lower PAF, higher pain sensitivity) was present in males but not in females. The authors discuss the lack of correlation.

In general, the study is rigorous, methodology is sound and the paper is well-written. Results are compelling and sufficiently discussed.

Strengths:

Strengths of this study are the pre-registration, proper sample size calculation, and data analysis. But also the presence of the analgesic effect of nicotine and the change in PAF.

Weaknesses:

It would even be more convincing if they had manipulated PAF directly.

Reviewer #2 (Public Review):

Summary: The study by Millard et al. investigates the effect of nicotine on alpha peak frequency and pain in a very elaborate experimental design. According to the statistical analysis, the authors found a factor-corrected significant effect for prolonged heat pain but not for alpha peak frequency in response to the nicotine treatment.

Strengths: I very much like the study design and that the authors followed their research line by aiming to provide a complete picture of the pain-related cortical impact of alpha peak frequency. This is very important work, even in the absence of any statistical significance. I also appreciate the preregistration of the study and the well-written and balanced introduction. However, it is important to give access to the preregistration beforehand.

Weaknesses: The weakness of the study revolves around three aspects:

(1) I am not entirely convinced that the authors' analysis strategy provides a sufficient signal-to-noise ratio to estimate the peak alpha frequency in each participant reliably. A source separation (ICA or similar) would have been better suited than electrode ROIs to extract the alpha signal. By using a source separation approach, different sources of alpha (mu, occipital alpha, laterality) could be disentangled.

(2) Also, there's a hint in the literature (reference 49 in the manuscript) that the nicotine treatment may not work as intended. Instead, the authors' decision to use nicotine to modulate the peak alpha frequency and pain relied on other, not suitable work on chronic pain and permanent smokers. In the present study, the authors use nicotine treatment and transient painful stimulation on non-smokers.

In my view, the discussion could be more critical for some aspects and the authors speculate towards directions their findings can not provide any evidence. Speculations are indeed very important to generate new ideas but should be restricted to the context of the study (experimental pain, acute interventions). The unfortunate decision to use nicotine severely hampered the authors' aim of the study.

Impact: The impact of the study could be to show what has not worked to answer the research questions of the authors. The authors claim that their approach could be used to define a biomarker of pain. This is highly desirable but requires refined methods and, in order to make the tool really applicable, more accurate approaches at subject level.

Reviewer #3 (Public Review):

In this manuscript, Millard et al. investigate the effects of nicotine on pain sensitivity and peak alpha frequency (PAF) in resting state EEG. To this end, they ran a pre-registered, randomized, double-blind, placebo-controlled experiment involving 62 healthy adults who received either 4 mg nicotine gum (n=29) or placebo (n=33). Prolonged heat and pressure were used as pain models. Resting state EEG and pain intensity (assessed with a visual analog scale) were measured before and after the intervention. Additionally, several covariates (sex at birth, depression and anxiety symptoms, stress, sleep quality, among others) were recorded. Data was analyzed using ANCOVA-equivalent two-wave latent change score models, as well as repeated measures analysis of variance. Results do not show *experimentally

relevant* changes of PAF or pain intensity scores for either of the prolonged pain models due to nicotine intake.

The main strengths of the manuscript are its solid conceptual framework and the thorough experimental design. The researchers make a good case in the introduction and discussion for the need to further investigate the association of PAF and pain sensitivity. Furthermore, they proceed to carefully describe every aspect of the experiment in great detail, which is excellent for reproducibility purposes. Finally, they analyze the data from almost every possible angle and provide an extensive report of their results.

The main weakness of the manuscript is the interpretation of these results. Even though some of the differences are statistically significant (e.g., global PAF, pain intensity ratings during heat pain), these differences are far from being experimentally or clinically relevant. The effect sizes observed are not sufficiently large to consider that pain sensitivity was modulated by the nicotine intake, which puts into question all the answers to the research questions posed in the study.